Filing Flows › 8-K events › 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals: other events
Form 8-K filed Oct 27, 2026 · items 8.01
FDA decisions60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
What the filing says
60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients ● All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR tests
Read the filing on SEC EDGAR →
What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →
60 Degrees Pharmaceuticals at a glance
60 Degrees Pharmaceuticals, Q2 2026: revenue $208K (+106% year over year). The chart follows the revenue to costs, profit and cash.
60 Degrees Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →
60 Degrees Pharmaceuticals’s other material 8-Ks
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.